The aim of the study was to prepare and statistically optimize transdermal formulation of antidiabetic drug Glimepiride (Glmp). In the present investigation Protransfersome gel (PTG) of glimepiride was prepared by modified coacervation phase separation technique and characterised for various parameters like vesicles shape, vesicles size and size distribution, entrapment efficiency and stability. Box-Benkhen model was chosen as optimization design. Three factors (amount of phospholipids, amount of surfactant and amount of drug) were varied at three levels Box-Benkhen statistical experimental design. These factors were found to have significant effects on the vesicular size (296.6±1.2nm), PDI(0.241±0.4) and drug loading(71.90±4.8%) and were optimized based on the desirability of the responses. The skin permeation studies were performed for 24 hours on pig ear skin using Franz diffusion cell. The flux value obtained from PTG (5.129±1.24 µg/cm 2 /h) was greater as compared to the drug suspension (0.430 µg/cm 2 /h). PTG formulation showed good stability at 4±1 0 C and after 3 months of storage there was no change in liquid crystalline nature, size of vesicles, drug content and other characteristic parameters observed. In vivo pharmacokinetic study of PTG showed significant drug release as compared to plain transdermal patch of the drug. Hence, present study reveals that PTG generates a new breakthrough for the transdermal delivery of Glimepiride with higher bioavailability, negligible gastrointestinal and hepatic side effects and increased patient compliance.
INTRODUCTION:
Diabetes mellitus (DM) is a serious world health problem defined as group of metabolic disease characterised by hyperglycemia resulting from defects in insulin secretion or insulin activity or both. Type 2 DM is associated with obesity and insulin resistance, together with defects in beta cell function 1 .
Glimepiride is a medium to long acting 3 rd generation sulphonylurea antidiabetic drug which is indicated to treat type 2 DM. It acts as an insulin secretagogue. It lowers blood sugar by stimulating release of insulin by pancreatic beta cells and by inducing increased activity of intracellular insulin receptor 2 . It is available in the form of tablet and suspension in the market with the dose of 2, 4, 8 mg per day.
Direct delivery of antidiabetic drug glimepride using oral approach is not suitable because it produces hypoglycaemia during initial hours of oral administration and irregular bioavailability due to low solubility in water and poor patient compliance. It is also associated with gastrointestinal side effects and hepatic side effects (like cholestatic jaundice) 3 . Thus, this necessity improved drug delivery via transfersome approach which enhanced delivery of this drug via the skin barrier, significantly improving bioavailability as well as patient compliance due to its ultradeformabilty property. The concept of ultradeformable or highly elastic vesicles was introduced in 1992 first by Gregor Cevc as new generation of vesicles, known as transfersomes, composed of phospholipids and surfactants called as edge activators 7, 8 . The edge activator refers to the single chain surfactants which causes destabilization of the lipid bilayer. In addition, it also increases the vesicle-elasticity or fluidity. Later in 1999, the second generation of the elastic vesicles were introduced by Van den Berg 7, 8 . These vesicles consist of a micelle forming and a bilayer forming surfactant as destabilizing and stabilizing portion, respectively. In order to overcome the stability problem liquid crystalline pro-ultraflexible lipid vesicles "Protransfersome" were proposed, that will be converted into ultraflexible lipid vesicles transfersomes also known as elastic liposomes, in situ by absorbing water from the skin 4, 5 . Protransfersomes provide higher stability and better skin penetration ability than the traditional lipid vesicles, e.g. liposomes, niosomes, etc 6 . The proposed Pro-T gel is a liquid crystalline gel in which the drug is intercalated within phospholipids 9 .
MATERIALS AND METHODS
Glimepiride was procured from Panacea Biotec, Delhi, India. L-α-phosphatidylcholine and sodium deoxycholate from Sigma Aldrich Co., St. Louis, U.S.A. Disodium hydrogen phosphate, Hydrochloric acid and sodium hydroxide were purchased from RFCL limited, New Delhi, India. All reagents used in this study were of analytical grade.
Preparation of ProTransfersomal Gel
Protransferosomal gel (ProT-gel) was prepared with slight modifications as reported by Perrett et al 10 . Soya phosphatidylcholine, sodium deoxycholate, drug (Glmp) and alcohol were weighed and collected in an amber colored vial. All the components were then mixed with the help of a magnetic bead at a temperature of 60-70⁰C, while keeping the open end of the vial closed, in order to prevent the loss of solvent. Then 100 mL phosphate buffer saline (pH 7.4) was added at the same temperature with continuous stirring, which lead to the formation of less viscous translucent liquid. This liquid composition was converted into the ProT-gel with overnight cooling at room temperature 10 .
Preparation of Transfersomes from ProTransfersome
ProT-gel (100 mg) was hydrated using 10 mL of phosphate buffer saline (pH 7.4) with manual shaking to produce transferosomal formulation for in-vitro evaluations.
Optimization

Response Surface Methodology -The Box-Behnken Model
Optimization was carried out with response surface methodology (RSM) by the means of Box-Behnken model. Factors such as amount of soya phosphatidylcholine, amount of sodium deoxycholate, and amount of drug (Glmp) were found to be significantly affecting the encapsulation efficiency of the drug, and size of the carrier, estimated by a series of hit and trial formulations. Hence, these three factors were varied at 3 levels while keeping the other factors such as type of alcohol, amount of alcohol, amount of buffer, stirring speed, and stirring temperature constant. The independent variables X 1 , X 2 , X 3 are listed in Table1. Based on the results of hit and trial formulations and literature study, appropriate ranges of the components were chosen as listed in table. Design Expert software was used to optimize the formulation and to develop the mathematical (quadratic) equations 11 . Size (Z-Average diameter) and the polydispersity index (PDI) of transfersomes derived from ProT-gel were analyzed by dynamic light scattering technique (DLS), using Zetasizer Nano ZS (Malvern Instruments Ltd., USA) at 25⁰C, and at an angle of 173⁰. The PDI relates with the width of vesicle size distribution and its small value (< 0.1) points towards homogeneity, while a high value (> 0.3) indicates high heterogeneity. All the measurements were conducted in triplicate 10 .Shape, size, and surface morphology of the transfersomes formed after hydration were confirmed by high resolution TEM at 300 kV (FEI, Technai G2 30 UTWIN). Samples were obtained by dispersing the ProT-gel (hydrated transfersomes) (0.1 mL) into 15 mL of double distilled water (diluted up to 150 times). A drop of prepared dispersion was stratified over a carbon-coated copper grid for approximately 15 min.
Excess dispersion was removed with a filter paper and the sample was subsequently dried in a desiccator for 60 minutes. Sample was then loaded on the probe and observed under transmission electron microscope.
Encapsulation Efficiency (%)
Hydrated ProT-gel formulation (1mL) was centrifuged for 35 min at 12,000 rpm and 4˚C using an ultracentrifuge (Hettich, Germany). The supernatant was analysed to determine the unentrapped fraction of drug (Glmp) using UV spectrophotometer (Shimadzu, USA) 12 .
The EE (%) was calculated by using the following:
.
Drug Loading (%)
The DL (%) was calculated by using the following:
Drug Release Study
The kinetics of drug (Glimepiride) release from the ultradeformable transferosomal preparation formulated as ProT-gel was determined by modified diffusion cell using pig ear skin as a membrane. The values were put into various kinetic equations and respective graphs were plotted such as: Zero order release kinetics, first order release kinetics, and Higuchi model. Release profiles were further evaluated using Korsmeyer-Peppas equation 15 to study the transport mechanism of the preparation.
In vitro Skin Permeation Studies
The pig skin was carefully cleaned with distilled water and mounted on a Franz diffusion cell assembly (Orchid Scientific, India) with an available diffusion area of 1.43 cm 2 . Fluid in diffusion cells was maintained at 37±0.5⁰C under continuous stirring 13 . The stratum corneum of skin confronted the donor section, and the dermis confronted the receptor section and the apparatus was assembled. Equal amounts of drug (Glmp) loaded Pro-T-gel formulation (optimised result by Box Benkhen statistical design) as well as drug (Glmp) suspended in hydroxyl propyl methyl cellulose (HPMC) gel (as control) were applied to the donor cells facing the topical side of the skin. Isotonic phosphate buffered saline (PBS, pH 7.4) having small amount of 40% (v/v) PEG 400, was added to the receptor chamber to mimic the transdermal water gradient across the epithelial and stratum corneum faced upward to the donor compartment (sink condition). Aliquots (1.0mL) of receptor solution were withdrawn periodically for 48 h and replaced with the same volume of pre-warmed receptor solution 14 . Samples were analysed by validated HPLC method at λ max (228 nm), and amount of drug permeated was calculated. Each preparation was studied in triplicate and the results represent the average value. All the measurements were conducted in triplicate.
Stability Studies
Optimized ProT-gel formulation was divided into 2 groups and stored at 4 ± 1⁰C and room temperature, respectively for 3 months in screw capped amber colored glass bottles. Formulations were evaluated for drug crystals under digital microscope, drug content remaining, vesicle size and PDI after every 30 days. Stability studies of each formulation were carried out in triplicate.
In vivo pharmacokinetic studies . Hair on backside of male wistar rat was removed on previous day of experiment. Dose of Glmp was selected by conducting hypoglycemic studies with dose of 1-10 mg/kg 16 . Following an overnight fast, rats were divided in to 3 groups (n=3) and were treated as follows:
GroupI
Statistical Analysis
Data analysis was implemented with the software, GraphPad Prism (5.0). The data were reported as mean ± S.D. (n = 3 or 6) and multiple comparisons of means (one way ANOVA, Dunnettpost test). Student's t-test was performed for comparing two samples. Results were said to be significant at ≥ 95% confidence interval, p< 0.05 and are shown as the mean ± SD.
RESULT AND DISCUSSION
Optimisation
Optimisation of Glmp loaded PTG was done by using Response Surface Methodology (RSM) : The BoxBehnken Model. RSM is a collection of statistical and mathematical techniques useful for developing, improving, and optimizing processes in which a response of interest is influenced by several variables and the objective is to optimize this response. RSM, which includes factorial design and regression analysis, helps in evaluating the important factors, building models to study the interactions between the variables, and selecting the optimum conditions of variables or desirable responses 11 . Box-Behnken statistical design was used to statistically optimize the significant formulation factors and evaluate their quadratic effects on size, PDI, zeta potential, and drug loading. The values of remaining parameters were kept constant throughout the Box-Behnken method. A design matrix comprising of 17 experimental runs with 5 centre points was constructed by varying 3 factors over 3 levels. The possible 17 combinations generated by the Design Expert (Version 9, Stat-Ease Inc., Minneapolis, MN) were run and responses were recorded. The independent variables and the responses for all 17 experimental runs are given in Table 2 . ISSN: 2250-1177 CODEN (USA): JDDTAO The above equation for drug loading indicates that the amount of soya lecithin, SDC, and drug, positively increase drug loading (%) in the ProT-gel.
From the above result the final optimised formulation was prepared which gave the result as given in Table 3 . 
Size, PDI and Entrapment Efficiency
To determine the vesicles shape Transmission Electron Microscopy (TEM) study was carried out (Figure1).
Vesicles size and size distribution was determine by optical microscope. The size was found to be 296 nm with the PDI of 0.25 and the maximum entrapment efficiency of vesicles was found to be 68%. 
In vitro Skin permeation studies
In vitro skin permeation studies were carried out on the optimized formulation and were compared with the drug suspension. Significant augmentation in the skin permeation of the drug has been observed ( Figure 2 ) with vesicular formulation as the percent cumulative drug permeated through the skin was 9.00±2.2 % for drug suspensions whereas the amount of drug permeated through the ProT-gel formulation was 82.50±9.8%. ProT-gel system provides a greater flux (5.129±1.24 µg/cm 2 /h) as compared to the drug suspension (0.430 µg/cm 2 /h) for Glimepiride ( Figure  2 ). Reduction in lag time for Glimepiride was observed with the ProT-gel system. After spontaneous transformation of ProT-gel into transferosomal vesicles (due to water permeation from the receptor compartment to the skin under non-occlusive conditions) two mechanism, (a) penetration enhancing effect and (b) the intact vesicular permeation through the skin, might simultaneously prevail the permeation of drug depending upon the vesicular composition, characteristics, and physicochemical properties of entrapped drug. Other reasons for enhanced permeation profile from ProT-gel carriers could be (a) better EE% of drug in transfersomes, (b) completely encapsulated drug within the vesicles, (c) alcohol providing penetration enhancement, and (d) membrane elasticity of the developed vesicular system. Due to spontaneous transformation of ProT-Gel into transferosomal vesicles, rapid drug permeation was detected for Glimepiride initially. Suspension demonstrated minimal to negligible permeation of drug over a period of 48 h. However, a sustained effect was observed with the ProT-gel formulation. 
Release study
The release from ProT-gel formulations was subjected to different model dependent kinetics (zero order, first order, Higuchi model release kinetics and KorsmeyerPeppas model, Fig.4 (a) , (b), (c) and (d) respectively). The release profile exhibiting maximum R 2 value was found to obey Higuchi model release kinetics for ProTgel formulations (Table 4) . Hence, ProT-gel formulations follow Higuchi model drug release mechanism which means formulation exhibits an initial burst release followed by sustained drug release.
Korsmeyer-Peppas kinetics model was also analysed to see whether it was following Fickian diffusion (n= 0.5), anomalous transport (0.5< n<1.0), case-II transport (n= 1), or super case-II transport (n>1). A graph was plotted between the percentage cumulative release and log time ISSN: 2250-1177 CODEN (USA): JDDTAO (h). Release exponent (n), and correlation coefficient was analysed (Fig. 4 d) . The release exponent (n) for the optimised ProT-gel formulation was found to be 0.8588. Therefore, the formulation followed Higuchi and anomalous transport for drug release. 
Stability Studies
The storage stability of the colloidal carriers is the foremost restriction in the preparation of clinically appropriate marketed formulations. The influence of aging on EE% was not too significant in the case of refrigerated temperature (Table 5 ). Reason for increased consistency of ProT-gel might be due to a possible molecular interaction of surfactant's polar head groups with the solvent and permeation of solvent into bilayer. Vesicle size increased whereas PDI decreased indicating complete swelling of bilayer as the solvent diffused into the bilayers completely with time and hence more uniform vesicles were formed upon storage. In vivo kinetic studies: In vivo studies in male wistar rats revealed that very low concentration of drug in plasma was achieved when micronized drug in gel was applied whereas when optimised Glmp loaded pro-transfersome patch was applied, it showed extensive increase in the drug release which was maintained over 48 hours ( Figure  3 ). These results established the sustained and prolonged delivery of Glimepiride from pro-T gel formulation and ability to maintain constant drug concentration over 48 hours. Based on in vivo results, it can be concluded that investigated carrier system provided accentuated delivery through alongwith controlled and prolonged delivery of Glimepiride.
CONCLUSIONS
Results of present study established that introduction of ProT-gel generates a new breakthrough for the transdermal delivery of Glimepiride and exhibited improved release kinetics. It anticipate numerous advantages for instance bypassing first pass metabolism, counting a higher bioavailability, negligible gastrointestinal side effect, less long term effects due to smaller amounts of drug administered, and most importantly increased patient compliance (with availability of patch system) which is foremost in treatment of such a life-time disorder. 
